CD274 and glioblastoma: Based on these results, a follow-up phase 1/2 combination study evaluating safety and efficacy of VXM01 in combination with the anti-PD-L1 checkpoint inhibitor avelumab has been initiated and is currently recruiting 30 patients with relapsed GBM (NCT03750071).